The rapidly changing bioanalytical industry can make it challenging for CROs to keep up with technology demands. However, organizations that establish strong and responsive partnerships with sponsor companies will be in the best position to deliver new value through new technology.
Bioanalytical outsourcing has changed dramatically in the past 30 years, which isn’t surprising when you consider how our economy, the healthcare market, technology, and drugs themselves have changed in that same period. To fully understand how we have arrived, as an industry, at a place where outsourcing is vital to our collective success, it is helpful to look back at where we started.
In this Q&A session, Sarah Rieveschl, Business Development Director at BioAgilytix, talks with us about the unique course her career has taken since joining our team six years ago.
Having been in the pharmaceutical and biotechnology industry for more than two decades – in roles spanning from R&D to manufacturing, for both small and large organizations – I have gained a unique perspective that I hope can provide helpful insight to young science major graduates before and after they enter the workforce.
The purchase price of a new bioanalytical platform is only a small part of the total cost of bringing it into the lab. We discuss the investments that must also be considered as part of the implementation process.
In this Team Q&A session, we speak to Dominic Phan, Business Development Associate at BioAgilytix, to discuss his experience joining the company as a new graduate two years ago and how his role has evolved since then.
How a CRO approaches technology investment is an excellent way to evaluate its priorities and commitment to strategic innovation. In this blog, Afshin Safavi discusses why starting with study requirements is the best way to decide which bioanalytical platforms to acquire.
Finding the right talent is challenging for any organization in any industry, but when you work in a complex field that requires highly skilled workers, it can be even more difficult. BioAgilytix’s CEO discusses the critical nature of hiring for a CRO, and approaches to attracting and retaining top scientific talent in a competitive industry.
In this Q&A session, we speak to Beth Heinz, Executive Director of Global Business Development and Key Accounts at BioAgilytix, as she discusses the evolution of her career with BioAgilytix and the opportunities she sees coming as the industry continues to advance.
It is anticipated that biologics will comprise 50% of the top 100 drugs by 2021. But, given the structural complexities of large molecule drugs, adherence to stringent quality standards will be a necessary part of effectively bringing these innovations to market. We discuss why it will be essential for pharma and biotech companies to align with outsourced partners that can deliver the quality science large molecule bioanalysis demands.
Services
Platforms
